Literature DB >> 20966417

Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort.

Gregory Y H Lip1, Lars Frison, Jonathan L Halperin, Deirdre A Lane.   

Abstract

BACKGROUND AND
PURPOSE: The risk of stroke in patients with atrial fibrillation (AF) is not homogeneous, and various clinical risk factors have informed the development of stroke risk stratification schemes (RSS). Among anticoagulated cohorts, the emphasis should be on the identification of patients who remain at high risk for stroke despite anticoagulation.
METHODS: We investigated predictors of thromboembolism (TE) risk in an anticoagulated AF clinical trial cohort (n = 7329 subjects) and tested the predictive value of contemporary RSS in this cohort: CHADS₂, Framingham, NICE 2006, American College of Cardiology/American Heart Association/European Society of Cardiology 2006, the 8th American College of Chest Physicians guidelines and the CHA₂DS₂-VASc schemes.
RESULTS: On multivariate analysis, significant predictors of TE were stroke/TIA (hazard ratio [HR], 2.24; P < 0.001), age 75 years or older (HR, 1.77; P = 0.0002), coronary artery disease (HR, 1.52; P = 0.0047), and smoking (HR, 2.10; P = 0.0005), whereas reported alcohol use (HR, 0.70; P = 0.02) was protective. Comparison of contemporary RSS demonstrated variable classification of AF patients into risk strata, although c-statistics for TE were broadly similar among the RSS tested and varied between 0.575 (NICE 2006) and 0.647 (CHA₂DS₂-VASc). CHA₂DS₂-VASc classified 94.2% as being at high risk, whereas most other RSS categorized two-thirds as being at high risk. Of the 184 TE events, 181 (98.4%) occurred in patients identified as being at high risk by the CHA₂DS₂-VASc schema. There was a stepwise increase in TE with increasing CHA₂DS₂-VASc score (P (trend) < 0.0001), which had the highest HR (3.75) among the tested schemes. The negative predictive value (ie, the percent categorized as "not high risk" actually being free from TE) for CHA₂DS₂-VASc was 99.5%.
CONCLUSIONS: Coronary artery disease and smoking are additional risk factors for TE in anticoagulated AF patients, whereas alcohol use appears protective. Of the contemporary stroke RSS, the CHA₂DS₂-VASc scheme correctly identified the greatest proportion of AF patients at high risk, despite the similar predictive ability of most RSS evidenced by the c-statistic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20966417     DOI: 10.1161/STROKEAHA.110.590257

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  134 in total

1.  MEDEX South Carolina: a progress report.

Authors:  K J Buhmeyer; A R Hutson
Journal:  J S C Med Assoc       Date:  1975-11

2.  [Epidemiology, clinical picture and management of atrial fibrillation].

Authors:  J Röther
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

Review 3.  Promise of factor Xa inhibition in atrial fibrillation.

Authors:  Sana M Al-Khatib; John H Alexander; Renato D Lopes; Kenneth W Mahaffey; Manesh R Patel; Christopher B Granger
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

Review 4.  Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.

Authors:  Wen-Gen Zhu; Qin-Mei Xiong; Kui Hong
Journal:  Tex Heart Inst J       Date:  2015-02-01

5.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Application of net reclassification index to non-nested and point-based risk prediction models: a review.

Authors:  Laine E Thomas; Emily C O'Brien; Jonathan P Piccini; Ralph B D'Agostino; Michael J Pencina
Journal:  Eur Heart J       Date:  2019-06-14       Impact factor: 29.983

7.  Recurrent Falls Among Elderly Patients and the Impact of Anticoagulation Therapy.

Authors:  Alexander S Chiu; Raymond A Jean; Matthew Fleming; Kevin Y Pei
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352

Review 8.  [Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].

Authors:  B Witzenbichler
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

9.  Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study.

Authors:  Chris Wilkinson; Andrew Clegg; Oliver Todd; Kenneth Rockwood; Mohammad E Yadegarfar; Chris P Gale; Marlous Hall
Journal:  Age Ageing       Date:  2020-12-16       Impact factor: 10.668

Review 10.  [Stroke prophylaxis in atrial fibrillation : When, how and for whom?]

Authors:  T Maurer; C Sohns
Journal:  Herz       Date:  2017-06       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.